Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance

SIMPLE SUMMARY: Venetoclax is a BH3-mimetics that specifically inhibits the antiapoptotic protein BCL-2. The drug has considerably expanded the treatment options of acute myeloid leukemia (AML) patients unfit for intensive treatment regimens. In recent phase III trials, combination of venetoclax wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Garciaz, Sylvain, Saillard, Colombe, Hicheri, Yosr, Hospital, Marie-Anne, Vey, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615921/
https://www.ncbi.nlm.nih.gov/pubmed/34830763
http://dx.doi.org/10.3390/cancers13225608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615921/
https://www.ncbi.nlm.nih.gov/pubmed/34830763
http://dx.doi.org/10.3390/cancers13225608

Ejemplares similares